Get Unlimited Plan at 75% OFF!

Advertisement
logo

Emcure Pharmaceuticals

EMCURE
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement

Emcure Pharmaceuticals Share price and Fundamental Analysis

View All Details
View All Details
Emcure Pharmaceuticals Ltd. was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.
Company Incorporation1981
ChairmanBerjis M Desai
Head QuartersNA
Previous NameNA

Key Metrics

Market Cap (Cr)
19,364
PE Ratio
31.87
Industry P/E
35.07
PEG Ratio
0
ROE
13.77%
ROCE
18.69%
ROA
7.77%
Total Debt (Cr)
824.36
Debt to Equity
0.29
Dividend Yield
0.19%
EPS
32.07
Book Value & P/B
149.28 x 6.85
Face Value
10
Outstanding Shares(Cr)
18.95
Current Ratio
2.08
EV to Sales
2.7

Included In

+More

Stock Returns

1 Week+0.29%
1 Month+13%
6 Months-28.66%
1 Year-24.71%
3 Years-24.71%
5 Years-24.71%

CAGR

1 Year CAGR

Revenue Growth

0%

Net Profit Growth

0%

Operating Profit Growth

0%

Dividend Growth

N/A

Stock Returns CAGR

-24.71%
no_data

No Stocks

Smart Score

1.6
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

/ View Standalone

Profit and Loss Statement

/ View Standalone
Credit Rating
Director Report
Chairman Report
Auditor Report

Balance sheet

/ View Standalone

Cashflow Statement

/ View Standalone
Mar 25

Promoters : 77.92%

FIIs : 3.07%

DIIs : 3.44%

Public : 15.57%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.04% of holding in March 2025 Qtr
FII Shareholding Increased by 0.02% to 3.07% in March 2025 Qtr
Promoter Shareholding Decreased by 0.02% to 77.92% in March 2025 Qtr
DII Shareholding Decreased by 0.43% to 3.44% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Emcure Pharmaceuticals Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Emcure Pharmaceuticals Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Emcure Pharmaceuticals Ltd. was originally incorporated as Emcure Pharmaceuticals Private Limited', as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited', through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.

The Company is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Emcure Pharmas were ranked as the largest pharmaceutical company in India in the gynecology, blood related and HIV antivirals therapeutic areas. It has 14 manufacturing facilities across India, which are capable in producing pharmaceutical and biopharmaceutical products of dosage forms, including oral solids, oral liquids, injectables including lipid, liposomal, lyophilized injectables, biologics, vaccines and complex APIs, including chiral molecules and cytotoxic products.

The Company keeps a strong track record in developing portfolios of differentiated products across several platforms, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched so far. In year 1999, Lasor Drugs Limited was amalgamated with the Company. Thereafter, Emcure Laboratories Private Limited., Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiraral Mehta Sales Private Limited were amalgamated with Company during period 2001. The Company established facility in Kurkumbh in 2006 and then commenced operations of injectables facility in Hinjawadi. The facility established by Company's Subsidiary, Gennova Biopharmaceuticals Limited at Hinjawadi was made operational.

The Company started operations in solid orals at facility in Jammu in 2009. During 2012, it acquired rights of BiCNUr, a branded oncology product prescribed for treatment of brain tumors, multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphoma. Through Subsidiary, Zuventus Healthcare Limited, a manufacturing facility was established in Bengaluru in year 2017 and finally, the Company received licence to work a factory at Sanand, Gujarat in 2018.

The Company has a portfolio of six commercialized and in-house manufactured biologics and biologics brands, Elaxim, Tenectase and Hamsyl, each launched into domestic market for the Financial Year 2021. The Company launched biosimilar for Tenecteplase, commonly used for acute myocardial infraction, and the biosimilar for Pegylated-asparaginase, commonly used for treating patients with leukemia. It hold the global patent for use of Tenectaplase to treat Acute Ischemic Stroke as a second indication in 2021.

The Company is proposing an Initial Public Offering of Rs 1100 Crore Equity Shares through Fresh Issue and an Offer for Sale upto 18,168,356 Equity Shares.

Emcure Pharmaceuticals Share Price

Emcure Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Emcure Pharmaceuticals Market Cap

Market capitalization of Emcure Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Emcure Pharmaceuticals is valued compared to its competitors.

Emcure Pharmaceuticals PE Ratio

Emcure Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Emcure Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Emcure Pharmaceuticals PEG Ratio

The PEG ratio of Emcure Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Emcure Pharmaceuticals ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Emcure Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Emcure Pharmaceuticals ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Emcure Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Emcure Pharmaceuticals Total Debt

Total debt of Emcure Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Emcure Pharmaceuticals Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Emcure Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Emcure Pharmaceuticals CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Emcure Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Emcure Pharmaceuticals Technical Analysis

Technical analysis of Emcure Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Emcure Pharmaceuticals Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Emcure Pharmaceuticals shares often struggle to rise above due to selling pressure.

Emcure Pharmaceuticals Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Emcure Pharmaceuticals ’s financial health and profitability.

Emcure Pharmaceuticals Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Emcure Pharmaceuticals Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Emcure Pharmaceuticals Financials

The financials of Emcure Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Emcure Pharmaceuticals Profit and Loss Statements

The profit and loss statement of Emcure Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Emcure Pharmaceuticals .

Emcure Pharmaceuticals Balance Sheet

The balance sheet presents a snapshot of Emcure Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Emcure Pharmaceuticals Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App